GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Goodwill-to-Asset

Cyclo Therapeutics (Cyclo Therapeutics) Goodwill-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Cyclo Therapeutics's Goodwill for the quarter that ended in Dec. 2023 was $0.00 Mil. Cyclo Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $13.25 Mil. Therefore, Cyclo Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 was 0.00.


Cyclo Therapeutics Goodwill-to-Asset Historical Data

The historical data trend for Cyclo Therapeutics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics Goodwill-to-Asset Chart

Cyclo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cyclo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cyclo Therapeutics's Goodwill-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclo Therapeutics's Goodwill-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Goodwill-to-Asset falls into.



Cyclo Therapeutics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Cyclo Therapeutics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/13.248
=0.00

Cyclo Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Goodwill to Asset (Q: Dec. 2023 )=Goodwill/Total Assets
=0/13.248
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclo Therapeutics  (NAS:CYTH) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Cyclo Therapeutics Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.
Executives
Vivien Wong director 6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc. 10 percent owner 520 BROAD STREET, NEWARK NJ 07120
William Conkling director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate director, officer: Chief Executive Officer C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic director 932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger director BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine director 600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow officer: SVP for Medical Affairs 4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems officer: Chief Medical Officer 91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine officer: Chief Financial Officer 21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak officer: Chief Regulatory Officer 12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit, 10 percent owner 966 HUNGERFORD DRIVE, ROCKVILLE MD 20850

Cyclo Therapeutics (Cyclo Therapeutics) Headlines

From GuruFocus